A naturally occurring metabolic compound, pyruvate, has been identified as a potent suppressor of inflammation in ulcerative colitis (UC), offering a promising new strategy for treating this chronic bowel disease. In both cellular and animal models, exogenous pyruvate effectively blocked the TNFα/NF-κB signaling pathway-central to inflammatory responses-and protected the integrity of the intestinal barrier. Most notably, the study uncovered cytosolic phospholipase A2 (cPLA2) as pyruvate's direct target, revealing a novel mechanism of action. These findings pave the way for developing a safe, oral therapy that tackles inflammation at its molecular root.

Ulcerative colitis (UC) is a chronic inflammatory disease marked by intestinal pain, bleeding, and impaired gut barrier function. At the h

See Full Page